沃森生物：目前，公司共有8个自主疫苗产品（14个品规）正式上市销售

Core Viewpoint - Watson Bio has a total of 8 self-developed vaccine products (14 specifications) officially on the market, aimed at preventing diseases caused by specific pathogenic microorganisms [1] Product Overview - The company’s vaccine products include: - 13-valent pneumococcal conjugate vaccine (vial type and pre-filled type) - Bivalent HPV vaccine (vial type and pre-filled type) - 23-valent pneumococcal polysaccharide vaccine (vial type and pre-filled type) - Haemophilus influenzae type b conjugate vaccine (vial type and pre-filled type) - Group A and C meningococcal polysaccharide conjugate vaccine (vial type and pre-filled type) - ACYW135 group meningococcal polysaccharide vaccine (vial type and pre-filled type) - Group A and C meningococcal polysaccharide vaccine (vial type) - Adsorbed acellular DTP combined vaccine (vial type) [1] Research and Development - The company’s 20-valent pneumococcal polysaccharide conjugate vaccine received the "Drug Clinical Trial Approval Notice" in April 2025 and is currently preparing for Phase I clinical research [1] - The company will disclose any substantial and phase-related progress in the research and development of its vaccine products in a timely manner [1]